ArticleCancer causes & control : CCC2026
Predictors of anal and cervical cancer screening uptake among adults with and without HIV: survey of a community-based health clinic network.
Article in Cancer causes & control : CCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePeople with HIV (PWH) in the United States (U.S.) are disproportionately impacted by human papillomavirus-related cancers. We aimed to identify sociodemographic, health, and social predictors of anal and cervical cancer screening uptake among adults with and without HIV.
methodsWe implemented a cross-sectional survey between April and June 2024 among adult patients receiving care at a community-based clinic network (predominantly based in Florida, U.S.) that delivers HIV prevention and treatment services. Outcomes included any receipt of anal cancer screening and guideline-adherent receipt of cervical cancer screening among eligible participants. We computed adjusted prevalence ratios (aPRs) to identify multilevel predictors associated with screening uptake.
resultsAmong the survey respondents, 412 (42%) were eligible for anal cancer screening and 294 (30%) for cervical cancer screening. Participants eligible for anal cancer screening included 88.8% living with HIV and 82.3% men. Men with HIV were more likely to receive anal cancer screening compared to men without HIV (aPR 1.57, 95% CI 1.08, 2.27). Among men with HIV, anal cancer screening uptake was associated with any precancer diagnosis and having three or more comorbidities. Women eligible for cervical cancer screening included 43.5% living with HIV. Women with HIV were less likely to receive guideline-adherent cervical cancer screening compared to women without HIV (aPR 0.60, 95% CI 0.47, 0.77). HIV-related disclosure concerns were associated with lower guideline-adherent cervical screening uptake among women with HIV (aPR 0.75, 95% CI 0.60, 0.94).
conclusionScreening-eligible participants with HIV were more likely to receive anal cancer screening and less likely to receive cervical cancer screening. Anal and cervical cancer screening uptake differed among subpopulations of people with HIV, including by race/ethnicity, household size, any precancer, comorbidities, and HIV-related stigma. Efforts to improve anal and cervical cancer screening uptake among high-risk and screening-eligible populations are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.